COMMENTARY

• JPMA Chief’s Comments to Endorse Coverage Review Send Ripples through Industry
  February 3, 2022

• Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
  January 17, 2022

• Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
  December 20, 2021

• Public-Private Collaboration Needed to Refine SaMD Regulatory System
  November 26, 2021

• MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
  November 16, 2021

• SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
  October 26, 2021

• LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
  October 19, 2021

• Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
  October 15, 2021

• Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
  October 13, 2021

• 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
  September 29, 2021

• CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
  August 3, 2021

• Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
  July 12, 2021

• Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
  June 22, 2021

• Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
  June 1, 2021

• Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
  February 9, 2021

• Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
  January 8, 2021

• Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
  December 28, 2020

• Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
  October 23, 2020

• IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
  September 16, 2020

• Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
  September 9, 2020

ページ